FlowNix (CEO Ha Ho-jin), a medical image analysis software development startup, announced on the 26th that it has attracted seed investment from Kakao Ventures, Digital Healthcare Partners (DHP), and Kangwon National University Technology Holdings.
Flonics is developing "Flonics-Streamliner," a software product that visualizes and analyzes blood flow in three dimensions. This product utilizes 4D flow MRI technology to precisely analyze hemodynamic data, including blood flow patterns, velocity, and direction within the heart and blood vessels. Unlike conventional image interpretation that focuses on vascular geometry, Flonics-Streamliner provides a comprehensive understanding of dynamic blood flow, helping to detect subtle pathological changes.
Cardiovascular disease is the leading cause of death worldwide, making early diagnosis and advanced analysis essential. However, existing imaging diagnostic technologies are limited to vascular morphology, limiting accurate diagnosis. FlowNix offers a noninvasive method that completes blood flow analysis within 30 minutes, enhancing convenience for medical professionals and providing a user interface optimized for clinical environments.
FlowNix is a team of medical image processing and AI experts, including Professor Ha Ho-jin of the Department of Mechanical and Biomedical Engineering at Kangwon National University and Professor Yang Dong-hyun of the Department of Radiology at Seoul Asan Medical Center. Their expertise and commercial viability have been proven through their experience completing government projects.
Using this investment, the company plans to complete prototype development within this year and proceed with technological advancements and clinical validation. It also plans to expand collaborations with domestic and international medical institutions, including Seoul Asan Medical Center, and introduce a usage-based billing model to support cost-effective hospital operations. Next year, it plans to obtain domestic approvals and expand into the global market.
Kakao Ventures Senior Analyst Jung Joo-yeon, who led this investment, said, “Flowonics has world-class 4D blood flow analysis technology and medical AI capabilities, so we expect it to lead clinical applications in the field of cardiovascular disease diagnosis.”
FlowNix CEO Ha Ho-jin stated, “We will commercialize innovative technologies to create tangible changes for both medical professionals and patients, and establish ourselves as a global standard solution in the diagnosis and treatment of cardiovascular diseases.”
You must be logged in to post a comment.